Prometic is a biopharmaceutical company based in Laval, Quebec, Canada. The firm was run by Pierre Laurin, chairman and CEO for 24 years. Since April 2019, it is now managed by Prometic CEO Kenneth Galbraith.
ProMetic develops therapeutics for unsatisfied clinical conditions in the field of hematology, oncology and autoimmune diseases.
ProMetic has also developed a proven technology to isolate and purify proteins. This technology is used by over 40 multinationals for the manufacturing of their own therapeutics: 12 of these companies have their respective drugs approved by the FDA / EMEA
Since filming, M. Laurin has left the company in December 2018.
The case was filmed in 2016 in Laval, Quebec, Canada at Prometic’s Canadian facilities.
Biopharma, Orphan Drugs, IP, Multinationals, Pharmaceutical industry, Biotech, complex drugs, human plasma, protein isolation, bringing new drugs to market, commercializing drugs, Laval, university research spinoffs, velcro business model, going public, IPO, joint ventures, international partnerships, American Red Cross, climate change disruption, royalty streams, doing business with governments in emerging markets, managing growth.
Production date: 2017
Pierre Laurin, former Prometic CEO
Frederic Dumais, former Prometic Senior Director
No Reviews found for this course.